Witryna2 cze 2024 · LEXINGTON, Mass., June 2, 2024 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address ... Witryna4 mar 2024 · LEXINGTON, Mass., March 4, 2024 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended ...
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® …
Witryna4 paź 2024 · Alexion, AstraZeneca Rare Disease acquired LogicBio Therapeutics (NASDAQ: LOGC), a Lexington, MA-based clinical-stage genomic medicine company. Under the terms of the agreement, Alexion,... Witryna16 maj 2024 · May 16, 2024 LEXINGTON, Mass. (AP) _ LogicBio Therapeutics Inc. (LOGC) on Monday reported a loss of $6.7 million in its first quarter. The Lexington, … christoph vescoli
LogicBio Therapeutics Receives FDA Fast Track Designation
WitrynaLogicBio Therapeutics Nov 2024 - Dec 20242 years 2 months Lexington, Massachusetts, United States CSO Cereius Cereius … Witryna3 paź 2024 · LogicBio is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release. About Alexion Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2024 acquisition of Alexion Pharmaceuticals, Inc. Witryna202 Notary jobs available in Woburn Highlands, MA on Indeed.com. Apply to Registrar, Real Estate Analyst, Real Estate Manager and more! christoph vesti